JP6563389B2 - Ｉｌ−２１結合タンパク質及びその使用 - Google Patents

Ｉｌ−２１結合タンパク質及びその使用 Download PDF

Info

Publication number
JP6563389B2
JP6563389B2 JP2016522133A JP2016522133A JP6563389B2 JP 6563389 B2 JP6563389 B2 JP 6563389B2 JP 2016522133 A JP2016522133 A JP 2016522133A JP 2016522133 A JP2016522133 A JP 2016522133A JP 6563389 B2 JP6563389 B2 JP 6563389B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016522133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529213A (ja
JP2016529213A5 (https=
Inventor
チャールズ レイ マッカイ
チャールズ レイ マッカイ
ディ ユー
ディ ユー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902377A external-priority patent/AU2013902377A0/en
Application filed by Monash University filed Critical Monash University
Publication of JP2016529213A publication Critical patent/JP2016529213A/ja
Publication of JP2016529213A5 publication Critical patent/JP2016529213A5/ja
Application granted granted Critical
Publication of JP6563389B2 publication Critical patent/JP6563389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016522133A 2013-06-27 2014-06-27 Ｉｌ−２１結合タンパク質及びその使用 Expired - Fee Related JP6563389B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013902377A AU2013902377A0 (en) 2013-06-27 A super-agonist monoclonal antibody to human IL-21 and its application in immunomodulation
AU2013902377 2013-06-27
PCT/AU2014/000673 WO2014205501A1 (en) 2013-06-27 2014-06-27 Il-21 binding proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2016529213A JP2016529213A (ja) 2016-09-23
JP2016529213A5 JP2016529213A5 (https=) 2018-11-01
JP6563389B2 true JP6563389B2 (ja) 2019-08-21

Family

ID=52140667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522133A Expired - Fee Related JP6563389B2 (ja) 2013-06-27 2014-06-27 Ｉｌ−２１結合タンパク質及びその使用

Country Status (8)

Country Link
US (3) US10077301B2 (https=)
EP (1) EP3013858B1 (https=)
JP (1) JP6563389B2 (https=)
CN (1) CN105579470B (https=)
AU (1) AU2014302028B2 (https=)
CA (1) CA2915882C (https=)
ES (1) ES2898650T3 (https=)
WO (1) WO2014205501A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077301B2 (en) 2013-06-27 2018-09-18 Monash University IL-21 binding proteins
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
AU2017207082B2 (en) * 2016-01-12 2023-07-13 Eisai Randd Management Co., Ltd. Anti-Myl9 antibody
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN119290543B (zh) * 2024-12-13 2025-03-21 天津医科大学总医院空港医院 一种同时检测淋巴组织中il-6、il-21与t细胞cd4表面分子的试剂盒及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP1753458A4 (en) 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
WO2007111714A2 (en) * 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
AU2007226856A1 (en) 2006-03-21 2007-09-27 Michael Rynkiewicz Methods for humanizing antibodies and humanized antibodies made thereby
US20080267910A1 (en) * 2007-03-09 2008-10-30 Wu Paul W Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences
US7883700B2 (en) * 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体
US10077301B2 (en) 2013-06-27 2018-09-18 Monash University IL-21 binding proteins

Also Published As

Publication number Publication date
US20210002362A1 (en) 2021-01-07
EP3013858A1 (en) 2016-05-04
US20160145332A1 (en) 2016-05-26
CA2915882C (en) 2022-12-06
EP3013858A4 (en) 2017-01-25
JP2016529213A (ja) 2016-09-23
US10787510B2 (en) 2020-09-29
US20190071497A1 (en) 2019-03-07
CA2915882A1 (en) 2014-12-31
WO2014205501A1 (en) 2014-12-31
EP3013858B1 (en) 2021-07-28
ES2898650T3 (es) 2022-03-08
US10077301B2 (en) 2018-09-18
AU2014302028A1 (en) 2016-01-21
AU2014302028B2 (en) 2019-09-19
CN105579470A (zh) 2016-05-11
CN105579470B (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
TWI853077B (zh) 新型抗ｃｄ３９抗體
JP7797198B2 (ja) ヒトｐｄ－１に対する二機能性分子
JP7807234B2 (ja) 二機能性抗ｐｄ－１／ｉｌ－７分子
JP7498714B2 (ja) Ｂ型肝炎ウイルスを中和する抗体およびその使用
JP2021137034A (ja) 抗ｃｔｌａ−４抗体およびその使用方法
JP6563389B2 (ja) Ｉｌ−２１結合タンパク質及びその使用
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
TW201829466A (zh) 抗－神經纖毛蛋白質(neuropilin)抗原－結合蛋白及其使用方法
US20210244825A1 (en) Il-21 antibodies
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
TW201620934A (zh) 特異性針對ｉｌ－２１之結合分子及其用途
AU2020336980B2 (en) Antibody compositions and methods for treating hepatitis B virus infection
TW202144420A (zh) 一種免疫細胞啟動劑的開發及應用
KR20250059415A (ko) B7-h3 항원-결합 분자
TW202245838A (zh) 用於治療b型肝炎病毒感染的組成物及方法
TW202411246A (zh) 經工程化之b型肝炎病毒中和抗體及其用途
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
TW201922280A (zh) 用於異位性皮膚炎之抗-il-33 療法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180723

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190507

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190724

R150 Certificate of patent or registration of utility model

Ref document number: 6563389

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees